Is Duolingo Stock a Buy in the Second Half of 2025?
Duolingo delivered a record performance in 2024.
It has the potential to sustain its growth momentum for the foreseeable future.
The stock's high valuation should give investors pause.
10 stocks we like better than Duolingo ›
Duolingo (NASDAQ: DUOL) stock has been on fire recently. In the last 12 months, it has risen 164% due to strong financial results and growth prospects.
If you missed out on that impressive rally, you may now be considering initiating a position in the stock. Here's what you need to know about this high-growth tech company.
Duolingo offers the world's No. 1 language learning app, and it enjoyed a stellar 2024. All key metrics, including revenue, bookings, and net income, reached record levels. Revenue surged 41% to $748 million, while net income rose more than sixfold from $14 million to $89 million.
And the company kicked off 2025 with a bang as well. For the first quarter, revenue jumped 38% year over year to $231 million, and bookings increased 38% to $272 million. Its adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) margin also improved about 900 basis points to 27.2% for the quarter.
The foundation of that strong performance is steady user growth. Monthly active users (MAU) reached 130.2 million, up 33% year over year. Daily active users saw an even bigger boost, up 49% to 46.6 million.
But overall user growth is just one part of the story. Duolingo is also improving its paid subscriber penetration rate, which increased year over year from 8.6% to 8.9%. Ongoing improvements to its content and user experience have led to better user engagement. The app's virtual assistant Lily, for example, allows Duolingo Max subscribers to practice their language skills in a fun, low-stakes environment to help them gain confidence over time.
Despite the company's already impressive reach and scale, its has a long growth runway. Management says the online language learning industry will be worth $47 billion in 2025, just a small slice of the $6 trillion of annual global education spending.
The company also estimates 2 billion people worldwide are learning a new language. And of its 130.2 million MAUs, less than one in 10 are paying subscribers, giving the tech company a huge opportunity to grow its user base and convert them over time.
To this end, Duolingo's continuous improvement efforts should significantly contribute to attracting, retaining, and converting normal learners to paid subscribers. It has added new subjects, such as music and math, in an effort to expand beyond its language courses.
Introducing artificial intelligence to the platform is another example of how Duolingo is working to improve learning outcomes. The company plans to enhance the user experience by making Lily and her environment 3D with interactive backgrounds to make conversations more immersive for learners.
While there are many things to like about Duolingo's solid execution and growth prospects, the stock doesn't come cheap. As of this writing, it boasts a price-to-earnings ratio of more than 250. Even if you believe this is a growth-first story and focus on its price-to-sales valuation instead, at 30 times trailing revenue, Duolingo is one of the most expensive large-cap stocks in the Nasdaq Composite index.
A premium is expected for most growth stocks, but paying such a hefty price comes with significant risk. Even a small hiccup that calls Duolingo's bullish outlook into question could see its valuation contract dramatically.
That potential for short-term volatility, however, shouldn't immediately scare investors away from a company that's clearly firing on all cylinders as it tackles a massive market opportunity. With that in mind, a position in Duolingo makes the most sense for investors with a long investment horizon of at least five years -- or an immense risk appetite.
Before you buy stock in Duolingo, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Duolingo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!*
Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Lawrence Nga has no position in any of the stocks mentioned. The Motley Fool recommends Duolingo. The Motley Fool has a disclosure policy.
Is Duolingo Stock a Buy in the Second Half of 2025? was originally published by The Motley Fool
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Company previously granted extension until June 30, 2025 to regain compliance with Nasdaq's Equity Rule requirement NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ('Helius' or the 'Company'), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on June 3, 2025, Helius received formal notice from the Nasdaq Hearings Panel of The Nasdaq Stock Market LLC (the 'Panel') indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth Listing Rules 5550(a)(2) (the 'Bid Price Rule'). The Panel further reminded the Company that it is also required to regain compliance with the equity requirement in Listing Rule 5550(b)(1) (the 'Equity Rule') by June 30, 2025 under the extension previously granted by the Panel. Accordingly, the Nasdaq Listing Qualifications hearing process will remain open until the Company has demonstrated compliance with all of The Nasdaq Stock Market's continued listing requirements. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain's ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information about PoNS or Helius Medical Technologies, visit Cautionary Disclaimer Statement Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as 'believe,' 'expect,' 'continue,' 'will,' 'goal,' 'aim' and similar expressions. Such forward-looking statements include, among others, but are not limited to, statements regarding the Company's ability to achieve and maintain compliance with the Nasdaq listing rules. The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law. Investor Relations Contact Philip Trip TaylorGilmartin Groupinvestorrelations@


CNBC
34 minutes ago
- CNBC
An options strategy to maximize gains and minimize risk in this cloud AI winner
Oracle (ORCL) is undergoing a resurgence fueled by its leadership in artificial intelligence services and robust growth in Oracle Cloud Infrastructure (OCI). With OCI emerging as a preferred platform for AI workloads, Oracle has secured major partnerships like the $500 billion Stargate project with OpenAI and SoftBank, positioning it as a key player in the AI revolution. ORCL's attractive valuation, strong profitability and recent breakout signal suggests significant upside potential — making it a compelling candidate for bullish exposure in a market recovery. Trade timing The timing for adding bullish exposure to ORCL is optimal, as the stock recently broke above its $155 resistance and bounced higher as it retested it as support. This breakout is coupled with outperformance relative to the S & P 500 with an upside target of $190, offering an attractive risk-to-reward profile for a long position. Fundamentals ORCL trades at a meaningful discount to its industry despite superior profitability and growth metrics, positioning it as an undervalued tech name with significant upside potential. Forward PE ratio: 24.5x vs. industry average 27.7x Expected EPS growth: 13% vs. industry average 11% Expected revenue growth: 13% vs. industry average 9% Net margins: 21.8% vs. industry average 9.8% Bullish thesis AI-driven resurgence : Oracle's OCI revenue grew 49% YoY to $2.7 billion in Q3 FY2025, driven by demand for AI workloads signaling a strong pipeline for AI and cloud contracts. Strategic AI partnerships : Oracle's role in the $500 billion Stargate project with OpenAI and SoftBank, alongside deploying over 131,000 Nvidia Blackwell GPUs, cements its position as a key player in AI infrastructure. Attractive valuation : ORCL trades at 24x forward earnings, below the Nasdaq-100's 27.5x, with projected revenue growth of 13% in FY2026 and 18% in FY2027, highlighting significant upside potential. Technical breakout : The breakout above $155, with an upside target of $190, confirms strong momentum and potential for further gains as investor confidence grows. The trade To capitalize on ORCL's potential upside, I'm buying an Aug. 15 $170/$190 Call Vertical @ $7.12 Debit. This entails: Buying the Aug $170 Call @ $11.15 Selling the Aug $190 Call @ $4.03 The maximum reward is $1,288 if ORCL is above $190 at expiration. The maximum risk is $712 if ORCL is below $170 at expiration. The breakeven point for this trade is $177.12. View this trade with updated prices at OptionsPlay. This strategy positions you to benefit from ORCL's potential rally, leveraging its technical breakout, AI-driven growth and undervaluation to profit from a high-quality tech name with defined risk. With Oracle's leadership in AI-related cloud services, this call vertical offers a compelling opportunity to capture upside potential in a thriving industry. DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.


News24
42 minutes ago
- News24
Budget 3.0 on track: Bonds extend gains as finance committee backs fiscal framework
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.